ProPhase Labs, Inc. · OTC:PRPH
ProPhase Labs — Investor Presentation (February 2026)
23 slides from ProPhase Labs's investor presentation, Feb 20, 2026
Slide 1: Winter 2026 Investor Presentation
Winter 2026 Investor Presentation ProPhaseLabs.com NASDAQ: PRPH
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Except for the historical information contained herein, this document contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives and initiatives, including o
Slide 3: ProPhase Labs Business Verticals
PROPHASE LABS BUSINESS VERTICALS ProPhase has entered into an initiative with Crown Medical Collections targeting Crown Medical Collections over $50 million in net near -term cash recovery form COVID -19 receivables. Crown $50 million net accounts Medical appointed as Special Counsel to launch litig
Slide 4: Our Best Is Yet To Come! Performance Track Record
OUR BEST IS YET TO COME! PERFORMANCE TRACK RECORD 2012 2017 2018 2020 2021 Ted Karkus, CEO, restructures Sold the Cold-EEZE cold remedy From 2018 to 2022, delivered Commenced CLIA lab services for Acquisition of Nebula Genomics. and turns around the Company. brand for $50m to Mylan shareholder value
Slide 5: Crown Medical Collections
CROWN MEDICAL COLLECTIONS ProPhase has entered into an initiative with Crown Medical Collections targeting over $50 million in net near -term cash recovery from COVID -19 receivables. • Crown Medical appointed Special Counsel to launch litigation against insurance companies. The team is now entering
Slide 6: ProPhase
ProPhase
Slide 7: BE-Smart Sale and Strategic Partnership Process
BE - Smart SALE AND STRATEGIC PARTNERSHIP PROCESS ProPhase has initiated an active sale and strategic partnership process for BE -Smart • Active sale & stra tegic partnership process underway, with the objective of generating a meaningful liquidity event while positioning the test for broader clinic
Slide 8: BE-Smart Esophageal Cancer Diagnostic in Final Stages of Preparation for Commercialization
BE - Smart ESOPHAGEAL CANCER DIAGNOSTIC IN FINAL STAGES OF PREPARATION FOR COMMERCIALIZATION ESOPHAGEAL ADENOCARCINOMA (EAC) – ONE OF THE DEADLIEST CANCERS • 16,000+ Estimated Deaths in 2023 in the U.S. 1 • 78.3% - 5 -Year Mortality Rate (2013 -2019) 1 • 21,000+ Estimated New Cases in 2023 1 • The c
Slide 9: Opportunity to Prevent Esophageal Cancer with Early and Accurate Diagnosis
OPPORTUNITY TO PREVENT ESOPHAGEAL CANCER WITH EARLY AND ACCURATE DIAGNOSIS Target Market ~ 67 million Prevalence of GERD in the U.S of 20% 1 (Census 337 million 2) Endoscopies: ~7mm Estimated average Prevalence of Barrett’s Esophagus in the cost per test: $1k - $2k U.S. is 5.6% of the population 337
Slide 10: Advantages of the BE-Smart Diagnostic Compared to Liquid Biopsies
ADVANTAGES OF THE BE - Smart ESOPHAGEAL CANCER DIAGNOSTIC COMPARED TO LIQUID BIOPSIES ✓ BE -Smart is designed to take EXISTING biopsy blocks from routine endoscopies, which is the standard of care for diagnosis of GER D, Barrett’s Esophagus and esophageal adenocarcinoma. No additional samples are ne
Slide 11: BE-Smart - Esophageal Cancer Diagnostic
BE - Smart - ESOPHAGEAL CANCER DIAGNOSTIC ProPhase is thrilled to appoint Dr. Joe Abdo , former CEO of Stella Announced full USPTO approval for issuance of U.S. patent protecting Diagnostics, to drive the commercialization of its BE -Smart diagnostic esophageal a denocarcinoma risk assessment.* Issu
Slide 12: Diagnostics Lab Relaunch Plan
DIAGNOSTICS LAB RELAUNCH PLAN Planned Laboratory Operations • ProPhase Labs plans to re -activate its previously licensed CLIA laboratory subsidiaries to operate as the testing laboratory for the BE -Smart esophageal cancer diagnostic. • The laboratories will be refocused exclusively on esophageal c
Slide 13: BE-Smart Overexpression in EAC Compared to Routine Markers
BE - Smart - OVEREXPRESSION IN EAC COMPARED TO ROUTINE MARKERS FOR PROGNOSTICATION AND THERAPY STLA101 EAC Expression Compared to Routine Targeted Therapy Markers 53/55 30286.7 10000.0 amol/ug 9500.0 9000.0 8500.0 8000.0 55/55 7500.0 Mean expression (amol/ug) 7000.0 6500.0 55/55 6000.0 55/55 51/55 5
Slide 14: BE-Smart Near Term Path to Commercialization
BE - Smart - ESOPHAGEAL CANCER DIAGNOSTIC NEAR TERM PATH TO COMMERCIALIZATION Filed US patent application on May 19, 2021 Initiated 1,000 patients on STLA101 assay with Mayo Clinic Completed first ~200 tests Submitted and presented interim results to ACG/ASCO -GI/SAGES/AACR/DDW in 2022 Filed all pat
Slide 15: Nebula Genomics
Nebul ) Genomics fd. 6 DNA Complete’ _
Slide 16: Meet George Church, Founder of Nebula Genomics and Scientific Advisor
MEET GEORGE CHURCH, FOUNDER OF NEBULA GENOMICS AND SCIENTIFIC ADVISOR Mission: To usher in the era of personal genomics by providing Nebula Genomics turns these breakthrough technologies into B2C and B2B products access to affordable and secure Whole Genome Sequencing. available around the globe. Pr
Slide 17: Nebula Genomics
NEBULA GENOMICS • The Company believes that Nebula is a compelling acquisition candidate, offering a uniquely diverse 16 -petabyte DNA dataset (equivalent to roughly 150 million ancestry SNP -based tests), with samples spanning 130 countries. We believe that Nebula’s dataset is one of the largest an
Slide 18: DNA Complete - Launched November 4, 2024
DNA COMPLETE® - LAUNCHED NOVEMBER 4, 2024 DNA Complete is a world -class Whole Genome Sequencing and Bioinformatics direct to consumer test offering. Whole Genome Sequencing (“WGS”) Technology Our WGS DNA technology analyzes virtually 100% of your DNA compared to typical DNA Ancestry tests that anal
Slide 19: DNA Complete
DNA COMPLETE® Direct To Consumer Launch of DNA Complete Shape The Future of Your Health and Explore Your Ancestry with DNA Complete Essential Pro Elite • Built a comprehensive marketing campaign featuring top DNA Test DNA Test DNA Test $195 $495 $1,495 influencers, managed by an experienced marketin
Slide 20: DNA Expand
DNA EXPAND Most Other DNA DNA Upload, Expansion and Analysis Data Upload Services • Consumers effortlessly upload their DNA data DNA data expansion. from other DNA Ancestr y tests to unlock our Expands raw DNA data more than No DNA data expansion. proprietary reports and advanced features. 50 times
Slide 21: Key Management and Advisors
KEY MANAGEMENT AND ADVISORS Ted Karkus Jason Karkus Kevin Quinn Dr. George Church Dr. Joe Abdo James McCullough Chairman & CEO President Chief Product Officer Advisory Board – Nebula ProPhase Labs Clinical ProPhase Labs Clinical ProPhase Labs, Inc. Nebula Genomics & Nebula Genomics Genomics Science
Slide 22: Investment Highlights
INVESTMENT HIGHLIGHTS Completed restructuring and transition to significantly leaner company for H2 2025 • Sold Pharmaloz Manufacturing • Shut down Nebula Genomics laboratory • Dramatically reduced headcount • Significantly reduced IT and related overhead Crown Medical Collections initiative targeti
Slide 23: Thank You
ProPhaseLabs .com Thank You TED KARKUS Chairman & CEO 626 RXR Plaza 6 th Floor Uniondale, NY 11556 INVESTOR RELATIONS CONTACT Dave Gentry, CEO RedChip Companies, Inc . 1-800 -REDCHIP (733 -2447 ) 1-407 -644 -4256 PRPH@redchip .com RETAIL INVESTOR RELATIONS John Boidman Renmark Financial Communicatio
ProPhase Labs — Investor Presentation (February 2026) on 6ix